FDA Taking “Risk-Based Approach” To Sequestration Cuts
This article was originally published in The Tan Sheet
Executive Summary
The agency will try to manage $319 million in potential funding reductions in a way that minimizes negative effects on health and safety, Commissioner Hamburg tells the Science Board, but significant layoffs seem unavoidable if sequestration is enacted.
You may also be interested in...
Sequestration Could Drive An FDA Resources Review
FDA and advocates wait to see how an estimated 7.8% budget cut would be implemented, if enacted. Former agency officials say sequestration could lead to hiring freezes and program delays.
Intercept’s Ocaliva: ‘Dangling’ PBC Indication At Risk As Near-Term NASH Approval Looks Unlikely
Accelerated approval for primary biliary cholangitis in 2016 came with three postmarketing requirements, but studies were terminated early; firm working toward sNDA submission in 2023 for regular approval, but US FDA says reports already are overdue and it expects to take PBC indication back to an adcomm.
Intercept’s OCA In NASH: When Hitting Surrogate Endpoint Is Not Enough For Accelerated Approval
Although US FDA reaffirmed its support of surrogate endpoints described in a 2018 draft guidance on NASH fibrosis, advisory committee members questioned the link to clinical benefit and said obeticholic acid’s serious risks made it difficult to consider the effect on the surrogate in a vacuum.